Skip to main
PLRX

PLRX Stock Forecast & Price Target

PLRX Analyst Ratings

Based on 3 analyst ratings
Hold
Strong Buy 0%
Buy 33%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Pliant Therapeutics Inc. has established a robust scientific foundation that positions it favorably within the competitive landscape of biopharmaceuticals, particularly with its lead product candidate, PLN-101095, demonstrating promising results in recent clinical trials. The company's experienced management team is adept at interacting with regulatory agencies, which mitigates associated risks and enhances the potential for successful drug development and commercialization. Additionally, the innovative integrin-targeted delivery platform presents a significant opportunity to unlock value across various disease areas, further strengthening the outlook for Pliant's stock.

Bears say

Pliant Therapeutics Inc is operating in a high-risk environment characterized by the potential for significant clinical setbacks, particularly given the historical difficulties in developing integrin inhibitors for idiopathic pulmonary fibrosis (IPF). The company faces notable regulatory risks that are common to biotech firms at a similar developmental stage, which could complicate trial designs and impact timelines for product candidates. Compounding these challenges, Pliant's decreased cash position and increased share count contribute to a negative outlook for the company's financial stability and market performance.

PLRX has been analyzed by 3 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 33% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pliant Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pliant Therapeutics (PLRX) Forecast

Analysts have given PLRX a Hold based on their latest research and market trends.

According to 3 analysts, PLRX has a Hold consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pliant Therapeutics (PLRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.